Drug intelligence / Profile preview

CE330

Development stage: Preclinical
Lead developer: Cello Therapeutics
Modality: Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Injection

Overview

CE330 is an investigational protein vaccine currently in preclinical development by Cello Therapeutics. The candidate is developed using the company's proprietary Cellular Nanoparticle (CNP) platform technology, which involves coating therapeutic cores with natural cell membranes to improve biocompatibility and targeted delivery. While specific molecular targets and indications for CE330 have not been publicly disclosed, the program is part of a broader pipeline focused on leveraging the CNP platform for cancer immunotherapy and the treatment of solid tumors.

Beyond the preview

Go deeper on CE330.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CE330.

Explore the full profile